Ozempic and Wegovy are increasingly available in Australia and worldwide to treat type 2 diabetes and obesity. The dramatic ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Amy Schumer reveals why she stopped taking Ozempic despite losing 30 pounds - Schumer said she tried the medication almost ...

Dr. Daniel Meltzer, a weight loss expert, suggests that it's possible to maintain weight loss after using GLP-1 medications by creating proper habits, including exercise and eating well. He emphasizes ...

Robert F. Kennedy Jr., President Trump's nominee to lead HHS, spoke highly of GLP-1 drugs at a Senate confirmation hearing ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has ruled that warnings about the risk should now be added to drugs like Ozempic, Wegovy and Mounjaro.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

They also don’t directly support behavior change, which Kathryn Ilonka Pollak, PhD, a professor in population health sciences ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...